Anales RANF

CPL-03 TOOLS AND DRUGS FOR PURINE RECEPTORS AND ECTONUCLEOTIDASES Christa Müller. University of Bonn, Germany The recently revived interest in drugs acting on purine receptors or otherwise interfering with purinergic signaling has led to the initiation and conduct of several clinical trials. Adenosine is one of the most potent immunosuppressive agents of the innate immune system, and the release of adenosine is a major contributor to the immune escape of cancer cells. This has caused a hype about purinergic drug development including P1 (adenosine) receptor antagonists for the subtypes A 2A and A 2B and ecto-nucleotidase inhibitors. Moreover, P2 receptor antagonists have shown great potential, e.g. for the treatment of inflammation and pain. Since more than 25 years, our group has focused on the development of tool compounds and drug molecules for protein targets involved in purinergic signaling. Recent advances in the field of assay development, fluorescent- and radiolabeled tool compounds, and potent, selective as well as multi-target drugs for purinergic receptors and ectonucleotidases will be presented.